Agenda and minutes

Venue: Committee Room 3 - Senedd. View directions

Contact: Fay Bowen 

Media

Senedd.TV: View the webcast

Items
Expected timing No. Item

Transcript

View the meeting transcript (PDF 594KB) View as HTML (393KB)

 

(14.00)

1.

Introductions, apologies, substitutions and declarations of interest

Minutes:

1.1       The Chair welcomed the Members to the Committee.

1.2       There were no apologies from Members. Apologies were received from the Auditor General for Wales.

1.3       Lee Waters AM declared an interest in that his wife is employed by Cwm Taf University Health Board (Item 4).

(14.00 - 14.10)

2.

Paper(s) to note

Supporting documents:

Minutes:

2.1 The papers were noted.

2.2 It was agreed that the Chair will write to the Permanent Secretary regarding the challenges digitalisation will bring to the Welsh Government and advise her that the Committee wish to discuss this issue with her further when she next attends Committee.

2.1

Introductory Session: Additional information from the Permanent Secretary, Welsh Government on Digitalisation (1 June 2017)

Supporting documents:

(14.10 - 15.15)

3.

Medicines Management: Evidence Session 2

Research Briefing

 

Judy Henley – Director of Contractor Services, Community Pharmacy Wales

Mark Griffiths - Chair of Community Pharmacy Wales

Mair Davies - Director, Royal Pharmaceutical Society Wales

Cheryl Way – RPS Board Member (Principal Pharmacist, Cardiff and Vale University Health Board and National Pharmacy and Medicines Management Lead, NHS Wales Informatics Service)

Supporting documents:

Minutes:

3.1 The Committee took evidence from Judy Henley, Director of Contractor Services, Community Pharmacy Wales; Mark Griffiths, Chair of Community Pharmacy Wales; Elen Jones, Practice and Policy lead for Royal Pharmaceutical Society Wales and Cheryl Way, RPS Board Member (Principal Pharmacist, Cardiff and Vale University Health Board and National Pharmacy and Medicines Management Lead, NHS Wales Informatics Service) as part of their inquiry into medicines management.

3.2 The Committee noted that Elen Jones had attended in place of Mair Davies, Director of RPS Wales due to sickness.

(15.30 - 16.45)

4.

Medicines Management: Evidence Session 3

PAC(5)-17-17 Paper 1 – Paper from Cwm Taf University Health Board

PAC(5)-17-17 Paper 2 – Paper from Powys Teaching Health Board

PAC(5)-17-17 Paper 3 – Paper from Abertawe Bro Morgannwg University Health Board

 

Allison Williams – Chief Executive, Cwm Taf University Health Board

Suzanne Scott-Thomas, Chief Pharmacist, Cwm Taf University Health Board

Professor Rory Farrelly – Acting Chief Operating Officer/Deputy Chief Executive & Director of Nursing and Patient Evidence, Abertawe Bro Morgannwg University Health Board

Judith Vincent – Clinical Director for Pharmacy and Medicines Management, Abertawe Bro Morgannwg University Health Board

Carol Shillabeer – Chief Executive, Powys Teaching Health Board

Karen Gully – Medical Director, Powys Teaching Health Board

Supporting documents:

Minutes:

4.1 The Committee took evidence from Allison Williams, Chief Executive, Cwm Taf University Health Board; Suzanne Scott-Thomas, Chief Pharmacist, Cwm Taf University Health Board; Professor Rory Farrelly, Acting Chief Operating Officer/Deputy Chief Executive & Director of Nursing and Patient Evidence, Abertawe Bro Morgannwg University Health Board; Judith Vincent, Clinical Director for Pharmacy and Medicines Management, Abertawe Bro Morgannwg University Health Board; Carol Shillabeer, Chief Executive, Powys Teaching Health Board and Karen Gully, Medical Director, Powys Teaching Health Board as part of their inquiry into medicines management.

4.2 Judith Vincent agreed to provide additional information on the work Professor Routledge is facilitating with experts on medicines related admissions regarding patient safety.

(16.45)

5.

Motion under Standing Order 17.42 to resolve to exclude the public from the meeting for the following business:

Item 6

Minutes:

5.1 The motion was agreed.

(16.45 - 17.00)

6.

Medicines Management: Consideration of evidence received

Minutes:

6.1 Members considered the evidence received.